PMID- 23425140
OWN - NLM
STAT- MEDLINE
DCOM- 20141014
LR  - 20220317
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 28
IP  - 3
DP  - 2014 Mar
TI  - Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index 
      (DLQI): the correlation between disease severity and psychological burden in 
      patients treated with biological therapies.
PG  - 333-7
LID - 10.1111/jdv.12106 [doi]
AB  - BACKGROUND: Multiple metrics evaluate the efficacy of psoriasis treatment, but 
      interestingly, the correlation between the mostly widely used clinical trial 
      efficacy end point, the physician-rendered Psoriasis Area Severity Index PASI 
      score and, the most widely used quality of life metric, the Dermatology Life 
      Quality Index DLQI, is not always high. OBJECTIVE: To perform a systematic review 
      to determine PASI to DLQI correlation. METHODS: RCTs of biological agents for the 
      treatment of moderate-to-severe psoriasis were reviewed in accordance with PRISMA 
      guidelines. The mean percentage PASI improvement and change in mean DLQI values 
      were recorded and compared for treatment groups from baseline to 10-16 weeks of 
      therapy. RESULTS: A search of the literature yielded 155 sources, of which 13 
      RCTs met inclusion and exclusion criteria. Percentage of PASI improvement from 
      baseline correlates with DLQI changes with an r(2) value of 0.80 from baseline 
      through weeks 10-16. When grouped by mean percentage reduction in PASI, agents 
      demonstrating >75% mean reduction in PASI demonstrated a mean DLQI improvement 
      over agents that achieved <75%-50% mean reduction in PASI or <50% mean reduction 
      in PASI [minimal clinically important difference (MCID) 3.2]. In addition, a 
      reduction in mean PASI of at least 75%, predicted a mean movement from DLQI band 
      3 to DLQI band 1, in all nine treatment arms demonstrating such efficacy. 
      CONCLUSIONS: Mean PASI and DLQI correlate predictably in patients with chronic 
      moderate-to-severe plaque psoriasis undergoing treatment with biological agents. 
      A reduction in PASI of at least 75% can translate to significant quality-of-life 
      improvement in patients treated with these therapies.
CI  - (c) 2013 The Authors Journal of the European Academy of Dermatology and Venereology 
      (c) 2013 European Academy of Dermatology and Venereology.
FAU - Mattei, P L
AU  - Mattei PL
AD  - The Johns Hopkins Hospital, Baltimore, MD, USA.
FAU - Corey, K C
AU  - Corey KC
FAU - Kimball, A B
AU  - Kimball AB
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20130221
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Biological Products)
SB  - IM
MH  - Biological Products/*therapeutic use
MH  - Humans
MH  - Psoriasis/pathology/psychology/*therapy
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Severity of Illness Index
MH  - *Stress, Psychological
EDAT- 2013/02/22 06:00
MHDA- 2014/10/15 06:00
CRDT- 2013/02/22 06:00
PHST- 2012/07/30 00:00 [received]
PHST- 2013/01/15 00:00 [accepted]
PHST- 2013/02/22 06:00 [entrez]
PHST- 2013/02/22 06:00 [pubmed]
PHST- 2014/10/15 06:00 [medline]
AID - 10.1111/jdv.12106 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 
      2013 Feb 21.